Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Income from Continuing Operations (2018 - 2025)

BioNexus Gene Lab's Income from Continuing Operations history spans 8 years, with the latest figure at 1036117.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 1036117.0 for Q4 2025, down 203.55% from a year ago — trailing twelve months through Dec 2025 was 2984607.0 (down 92.4% YoY), and the annual figure for FY2025 was 2984607.0, down 87.55%.
  • Income from Continuing Operations for Q4 2025 was 1036117.0 at BioNexus Gene Lab, down from 708991.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 351515.0 in Q4 2023 to a low of 2609189.0 in Q3 2023.
  • The 5-year median for Income from Continuing Operations is 108031.5 (2022), against an average of 334778.85.
  • Peak annual rise in Income from Continuing Operations hit 329.64% in 2023, while the deepest fall reached 3271.0% in 2023.
  • Year by year, Income from Continuing Operations stood at 115979.0 in 2021, then plummeted by 231.98% to 153071.0 in 2022, then skyrocketed by 329.64% to 351515.0 in 2023, then crashed by 197.1% to 341331.0 in 2024, then plummeted by 203.55% to 1036117.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 1036117.0, 708991.0, and 616172.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.